Bone marrow transplantation for chronic myelogenous leukemia

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Chronic myelogenous leukemia (CML) in chronic phase (CP) patients under 50 with HLA-identical siblings typically undergo bone marrow transplantation (BMT) within one year of diagnosis.
• Projected disease-free survival for these patients is 70-80% at 4 years, with many achieving a cure.
• BMT outcomes are less favorable for patients with advanced CML.

Purpose of the Study:

• To review current standards and emerging strategies for bone marrow transplantation in chronic myelogenous leukemia.
• To evaluate transplant conditioning regimens, graft-versus-host disease (GVHD) prevention, and donor selection.
• To explore the role of molecular monitoring and autografting in CML treatment.

Main Methods:

• Review of established BMT protocols for CML.
• Comparison of conditioning regimens: cyclophosphamide/total-body irradiation vs. busulphan/cyclophosphamide.
• Assessment of GVHD prophylaxis using cyclosporine and methotrexate.
• Evaluation of polymerase chain reaction (PCR) for monitoring BCR-ABL transcripts.
• Consideration of autografting as an alternative.

Main Results:

• Cyclophosphamide/TBI and busulphan/cyclophosphamide show similar efficacy for conditioning.
• Cyclosporine and methotrexate are optimal for GVHD prevention.
• Non-enlarged spleens do not necessitate splenectomy or radiotherapy.
• "Matched" volunteer marrow donors yield fewer successful outcomes.
• PCR monitoring of BCR-ABL transcripts may identify relapse risk.
• Autografting offers potential for prolonged survival or cure in select patients.

Conclusions:

• Early BMT is crucial for eligible CP CML patients.
• Optimal conditioning and GVHD prophylaxis are established.
• Molecular monitoring and autografting represent important advancements in CML management.
• Further research into alternative donor sources and post-transplant monitoring is warranted.